150 related articles for article (PubMed ID: 26071430)
1. Statistical challenges in assessing potential efficacy of complex interventions in pilot or feasibility studies.
Wilson DT; Walwyn RE; Brown J; Farrin AJ; Brown SR
Stat Methods Med Res; 2016 Jun; 25(3):997-1009. PubMed ID: 26071430
[TBL] [Abstract][Full Text] [Related]
2. Decision-theoretic designs for small trials and pilot studies: A review.
Hee SW; Hamborg T; Day S; Madan J; Miller F; Posch M; Zohar S; Stallard N
Stat Methods Med Res; 2016 Jun; 25(3):1022-38. PubMed ID: 26048902
[TBL] [Abstract][Full Text] [Related]
3. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
Zhou H; Lee JJ; Yuan Y
Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
[TBL] [Abstract][Full Text] [Related]
4. Approximately optimal designs for phase II clinical studies.
Stallard N
J Biopharm Stat; 1998 Jul; 8(3):469-87. PubMed ID: 9741860
[TBL] [Abstract][Full Text] [Related]
5. Sample size determination for phase II clinical trials based on Bayesian decision theory.
Stallard N
Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
[TBL] [Abstract][Full Text] [Related]
6. Bayesian two-stage designs for phase II clinical trials.
Tan SB; Machin D
Stat Med; 2006 Oct; 25(19):3407-8. PubMed ID: 16847890
[No Abstract] [Full Text] [Related]
7. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.
Lin R; Coleman RL; Yuan Y
J Natl Cancer Inst; 2020 Jan; 112(1):38-45. PubMed ID: 30924863
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the data combination rule for seamless phase II/III clinical trials.
Hampson LV; Jennison C
Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892
[TBL] [Abstract][Full Text] [Related]
9. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
10. Decision-theoretic designs for phase II clinical trials allowing for competing studies.
Stallard N
Biometrics; 2003 Jun; 59(2):402-9. PubMed ID: 12926725
[TBL] [Abstract][Full Text] [Related]
11. Monitoring event times in early phase clinical trials: some practical issues.
Thall PF; Wooten LH; Tannir NM
Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
[TBL] [Abstract][Full Text] [Related]
12. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
13. A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups.
Yin J; Qin R; Sargent DJ; Erlichman C; Shi Q
J Biopharm Stat; 2018; 28(3):451-462. PubMed ID: 28448747
[TBL] [Abstract][Full Text] [Related]
14. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial.
Zohar S; Teramukai S; Zhou Y
Contemp Clin Trials; 2008 Jul; 29(4):608-16. PubMed ID: 18201945
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
16. Optimal sample sizes for phase II clinical trials and pilot studies.
Stallard N
Stat Med; 2012 May; 31(11-12):1031-42. PubMed ID: 22052407
[TBL] [Abstract][Full Text] [Related]
17. Quality of reporting of pilot and feasibility cluster randomised trials: a systematic review.
Chan CL; Leyrat C; Eldridge SM
BMJ Open; 2017 Nov; 7(11):e016970. PubMed ID: 29122791
[TBL] [Abstract][Full Text] [Related]
18. Stopping rules for phase II studies.
Stallard N; Whitehead J; Todd S; Whitehead A
Br J Clin Pharmacol; 2001 Jun; 51(6):523-9. PubMed ID: 11422011
[TBL] [Abstract][Full Text] [Related]
19. Bayesian methods for pilot studies.
Willan AR; Thabane L
Clin Trials; 2020 Aug; 17(4):414-419. PubMed ID: 32297539
[TBL] [Abstract][Full Text] [Related]
20. Flexible designs for phase II comparative clinical trials involving two response variables.
Bersimis S; Sachlas A; Papaioannou T
Stat Med; 2015 Jan; 34(2):197-214. PubMed ID: 25274584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
